Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 11/20 | 0.66 |
| ▸ | RAF1 | P04049 | 2/20 | 0.60 |
| ▸ | KDR | P35968 | 5/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.59 |
| ▸ | AXL | P30530 | 1/20 | 0.58 |
| ▸ | BRAF | P15056 | 1/20 | 0.57 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22505561 | 0.90 | KDR (0.60) | FLT3KDRPDGFRABRAFRIPK2 | |
| SCHEMBL22505582 | 0.90 | FLT3 (0.64) | FLT3AXLBRAF | |
| SCHEMBL22505622 | 0.89 | FLT3 (0.69) | FLT3BRAF | |
| SCHEMBL22505620 | 0.89 | FLT3 (0.69) | FLT3RAF1BRAF | |
| SCHEMBL22505710 | 0.89 | KDR (0.58) | FLT3RAF1KDRPDGFRABRAF | |
| SCHEMBL22505597 | 0.89 | KDR (0.58) | FLT3KDRPDGFRABRAFRIPK2 | |
| SCHEMBL22505687 | 0.89 | FLT3 (0.85) | FLT3 | |
| SCHEMBL22505675 | 0.88 | KDR (0.68) | FLT3KDRPDGFRABRAFRIPK2 | |
| SCHEMBL22505734 | 0.87 | BRAF (0.62) | FLT3RAF1PDGFRABRAF | |
| SCHEMBL22505642 | 0.87 | KDR (0.58) | FLT3KDRPDGFRAAXLRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800741-B2 | Quinoline compound, preparation method and medical use therefor | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2020-10-13 | — | — | US | disclosed |
| US-10800741-B2 | Quinoline compound, preparation method and medical use therefor | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2020-10-13 | — | — | US | disclosed |
| US-9464066-B2 | Deuterated compounds useful for treating neurodegenerative diseases | PHARMATROPHIX, INC. (US) | 2016-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800741-B2 | Quinoline compound, preparation method and medical use therefor | WEE2, WEE1, HASPIN | FLT3 238/4885RAF1 11/4885KDR 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.